Anticholinergic and sedative medication use in persons with HIV: defining the evidence for risks on cognition

AIDS. 2024 Nov 1;38(13):1885-1887. doi: 10.1097/QAD.0000000000003994. Epub 2024 Sep 26.

Authors

Karl Goodkin¹, Alan Winston², Esteban Martinez³, Robert Paul⁴

Affiliations

¹ Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) [formerly the AIDS Clinical Trials Group], Los Angeles, California, USA.
² Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
³ Infectious Diseases Unit, Hospital Clínic & University of Barcelona, Barcelona, Spain.
⁴ Missouri Institute of Mental Health, University of Missouri, St. Louis, Missouri, USA.

PMID: 39325004
DOI: 10.1097/QAD.0000000000003994

No abstract available

MeSH terms

Cholinergic Antagonists* / administration & dosage
Cholinergic Antagonists* / adverse effects
HIV Infections* / drug therapy
Humans
Hypnotics and Sedatives* / administration & dosage
Hypnotics and Sedatives* / adverse effects
Risk Assessment

Substances

Hypnotics and Sedatives
Cholinergic Antagonists

Grants and funding